Clinical Trial Update: Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) [NA]

View source ↗

Summary

Clinical trial RAPY90D investigates personalized Yttrium-90 dosimetry-based radioembolization with curative intent for unresectable hepatocellular carcinoma acr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | NA | Status: ACTIVE_NOT_RECRUITING